CHENGDU, China, Sept. 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for...
Hence then, the article about kelun biotech s new drug application for its novel next generation selective ret inhibitor a400 ep0031 accepted for review by the nmpa for the treatment of ret fusion positive nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC )
Also on site :
- Nigel Farage’s Reform UK party receives second big donation from crypto investor
- Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO
- Russian Ambassador to Canada: “Ottawa” supported use of force against Iran, & our relations have been in a ‘Deep Freeze’ since 2014